This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
SNY Stock Falls After Board Suddenly Makes Leadership Change
by Zacks Equity Research
Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudson's mandate and names Belen Garijo as successor amid investor skepticism.
SNYNegative Net Change ALKSNegative Net Change CSTLPositive Net Change IMCRPositive Net Change
pharmaceuticals
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates
by Zacks Equity Research
MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.
MRKPositive Net Change VRTXPositive Net Change MRNAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
by Kinjel Shah
Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.
MRKPositive Net Change MRNAPositive Net Change SMMTPositive Net Change
pharmaceuticals
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
by Zacks Equity Research
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
NVSPositive Net Change ALKSNegative Net Change BAYRYPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.
REGNPositive Net Change ALKSNegative Net Change RARENegative Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
by Zacks Equity Research
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
ALNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change ALKSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
by Ekta Bagri
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
ZTS stock rises after Q4 earnings and revenues top estimates, as strong international growth and upbeat 2026 guidance offset U.S. softness.
ALKSNegative Net Change EXELPositive Net Change ZTSPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific
by Zacks Equity Research
Eli Lilly, Marriott and Fortinet lead Zacks' top analyst picks after earnings beats and strong outlooks across pharma, travel and cybersecurity.
MARNegative Net Change LLYPositive Net Change FTNTPositive Net Change GSITPositive Net Change KEQUNegative Net Change
computers consumer-discretionary pharmaceuticals tech-stocks
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
by Zacks Equity Research
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals